Zacks Investment Research downgraded shares of Koninklijke DSM NV (OTCMKTS:RDSMY) from a buy rating to a sell rating in a report released on Wednesday morning.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Koninklijke DSM NV (OTCMKTS:RDSMY) opened at 16.55 on Wednesday. The firm has a market capitalization of $11.55 billion, a P/E ratio of 38.67 and a beta of 1.44. The stock’s 50 day moving average price is $17.08 and its 200 day moving average price is $15.63. Koninklijke DSM NV has a 12 month low of $11.33 and a 12 month high of $17.88.

Koninklijke DSM NV Company Profile

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Get a free copy of the Zacks research report on Koninklijke DSM NV (RDSMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Koninklijke DSM NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM NV and related companies with's FREE daily email newsletter.